NASDAQ : CYCN
Cyclerion Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 23.520007 USD (At close: Sep 8, 2026) · Market cap 15.48M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 15.48M |
| Enterprise Value | 14.09M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 658,189 |
| Shares Outstanding | 658,189 |
| Shares Change (YoY) | +44.12% |
| Shares Change (QoQ) | +1.09% |
| Owned by Insiders (%) | 176.78% |
| Owned by Institutions (%) | 230.52% |
| Float | 1.18M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.15 |
| Forward PS | n/a |
| PB Ratio | 2.81 |
| P/TBV Ratio | 3.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 7.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.82 |
| Quick Ratio | 0.75 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -98.22% |
| Return on Assets (ROA) | -52.33% |
| Return on Invested Capital (ROIC) | -62.46% |
| Return on Capital Employed (ROCE) | -134.15% |
| Weighted Average Cost of Capital (WACC) | 13.90% |
| Revenue Per Employee | $1.90M |
| Profits Per Employee | -$6.71M |
| Employee Count | 1 |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.75 |
| 52-Week Price Change | -77.95% |
| 50-Day Moving Average | 26.24 |
| 200-Day Moving Average | 17.92 |
| Relative Strength Index (RSI) | 41.24 |
| Average Volume (20 Days) | 13,793 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 52,394 |
| Short Previous Month | 44,969 |
| Short % of Shares Out | 7.96% |
| Short % of Float | 4.45% |
| Short Ratio (days to cover) | 2.20 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.90M |
| Gross Profit | 303,000 |
| Operating Income | -6.82M |
| Pretax Income | -6.71M |
| Net Income | -6.71M |
| EBITDA | n/a |
| EBIT | -6.82M |
| Loss Per Share | -$12.12 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.39M |
| Total Debt | n/a |
| Net Cash | 1.39M |
| Net Cash Per Share | $2.11 |
| Equity (Book Value) | 5.09M |
| Book Value Per Share | 8.37 |
| Working Capital | -329,000 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -4.45M |
| Capital Expenditures | -66,000 |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -4.52M |
| FCF Per Share | -$6.86 |
Margins
| Measure | Value |
|---|
| Gross Margin | 15.95% |
| Operating Margin | -359.16% |
| Pretax Margin | -353.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -44.12% |
| Shareholder Yield | -44.12% |
| Earnings Yield | -43.33% |
| FCF Yield | -29.18% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 467.81% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 16, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -56.01 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |